Skip to main content
Publications
Hauber B, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Hartry A, Lee D, Wilson H, Hoffman DL, Weiberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Frangiosa T, Biggar V, Slota C, Romano (DeMuro) C , DiBenedetti D . Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis . Neurol Ther. 2023 Apr;12(2):505-27. doi: 10.1007/s40120-023-00445-0
DiBenedetti D , Menne H, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Heithoff K, Hartry A, Oberdhan D, Wilson H, Hoffman DL, Weinberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Hauber B, Romano (DeMuro) C . Technical review of clinical outcomes assessments across the continuum of Alzheimer's disease . Neurol Ther. 2023 Apr;12(2):571-95. doi: 10.1007/s40120-023-00443-2
Forns J , Dudukina E, Hagg D, Szentkuti P, Gembert K, Plana E , Gilsenan A , Horvath-Puho E, Ehrenstein V, Reutfors J, Rebordosa C . Risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: a population-based cohort study . Neurol Ther. 2022 Dec 1;11(4):1659-76. doi: 10.1007/s40120-022-00396-y
Walley D , Twiss J , Doward L , Balp MM, Brass C, Loeffler J, Lopez P, Cai J, Cryer D, Anstee Q, Sanyal A. Patient-reported symptoms and impact in nonalcoholic steatohepatitis: an evaluation of the NASH-CHECK, a novel PROM in NASH . Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. Digital. [abstract] J Hepatol. 2020 Jan; 73:S422-3. doi: 10.1016/S0168-8278(20)33053-1
Breckons M, Doward L , McSweeney L, Balp MM, Twiss J , Oluboyede Y, Vale L, Ternent L, Brass C, Sanyal A, Anstee Q. Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis . Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. digital. [abstract] J Hepatol. 2020 Jan; 73:S423. doi: 10.1016/S0168-8278(20)33053-1
Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AL, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano C , Williams VSL , Vissing J, Zhang Auberson L, Wu M, de Vera A, Papanicolaou DA, Amato AA, RESILIENT Study Group. Safety and efficacy of intravenous bimagrumab in inclusion body myositis: a phase 2b, randomised, double-blind, placebo-controlled study (RESILIENT) . Lancet Neurol. 2019 Sep;18(9):834-44.
Doward L , Balp MM, Twiss J , Slota C, Cryer D, Langford A, Collen R, Agashivala N, Brass C, Anstee QM, Sanyal A. Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis . Poster presented at the 2018 EASL International Liver Conference; April 13, 2018. Paris, France. [abstract] J Hepatol. 2018 Apr; 68(Suppl 1):S570.
Doward LC , Balp MM, Stewart KE, Cryer D, Langford A, Twiss J , Agashivala N, Brass C, Anstee QM, Sanyal A. Exploring the patient perceived impact of non-alcoholic steatohepatitis . Poster presented at the 2017 EASL International Liver Conference; April 2017. Amsterdam, The Netherlands. [abstract] J Hepatol. 2017 Apr; 66(1 Supplement):S422-3. doi: 10.1016/S0168-8278(17)31208-4